A retrospective study to determine correlation of sacubitril/valsartan doses below lowest approved doses (24/26 mg tablet) with reduction in NT-proBNP and associated beneficial effects in patients with HFrEF
Latest Information Update: 14 Dec 2020
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Pharmacodynamics
- 14 Dec 2020 New trial record
- 05 Dec 2020 Results published in the Clinical Cardiology